Now Playing
Opinion|Videos|June 5, 2024
Unique Challenges in Managing Adverse Events Associated with CAR T-Cell Therapy
A panel of experts on multiple myeloma give an overview of unique challenges in managing adverse effects associated with CAR T-cell therapy as compared with other cancer therapies.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- What are some of the unique challenges in managing adverse events associated with CAR T-cell therapy compared with other cancer therapies?
Advertisement
Related to this article
Updated NCCN Guidelines for multiple myeloma add a dedicated MRD testing framework and expand recommended MRD assessment timepoints.
Experts discussed whether CAR T cells or bispecific antibodies should be used first in relapsed/refractory multiple myeloma at the 2026 SOHO Annual Meeting.
The FDA’s decision on iberdomide is a “landmark approval” for those with multiple myeloma, according to Surbhi Sidana, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
2
Screening for CHIP Mutations to Guide CAR T Cell Candidacy in Lymphoma
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Daraxonrasib Receives FDA Breakthrough Therapy Status in 1L Metastatic PDAC
5